重组人脑利钠肽联合米力农治疗对充血性心力衰竭患者临床疗效及心功能的影响  

Effect of Recombinant Human Brain Natriuretic Peptide Combined with Milrinone Treatment on Clinical Efficacy and Cardiac Function in Patients with Congestive Heart Failure

作　　者：岳玉华 YUE Yuhua(Department of No.3 Internal Medicine,Zibo Zichuan District Hospital,Zibo 255100,China)

机构地区：[1]淄博市淄川区医院内三科,山东淄博255100

出　　处：《反射疗法与康复医学》2025年第7期157-159,163,共4页Reflexology And Rehabilitation Medicine

摘　　要：目的探讨重组人脑利钠肽(rhBNP)联合米力农治疗对充血性心力衰竭(CHF)患者的影响。方法选取2022年2月—2023年12月淄博市淄川区医院收治的90例CHF患者为研究对象,按随机抛硬币法将其分为对照组和观察组,各45例。对照组采用米力农治疗,观察组采用米力农联合rhBNP治疗,两组均持续治疗7 d。对比两组的临床疗效、心功能、心肌标志物、不良反应发生情况。结果观察组治疗总有效率为95.56%,高于对照组的75.56%,差异有统计学意义(P<0.05)。治疗后,两组左室射血分数均高于治疗前,且观察组高于对照组,两组左室舒张末期内径、左室收缩末期内径均短于治疗前,且观察组均短于对照组,差异有统计学意义(P<0.05);两组氨基末端脑利钠肽前体水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论rhBNP联合米力农治疗CHF患者的疗效显著,能够有效促进患者心功能的改善,降低心肌标志物水平,且安全性高。Objective Exploring the effect of recombinant human brain natriuretic peptide(rhBNP)combined with milrinone treatment on patients with congestive heart failure(CHF).Methods Selecting 90 patients with CHF admitted to Zibo Zichuan District Hospital from February 2022 to December 2023 as the research subjects,according to the random coin toss method,they were divided into a control group and an observation group,with 45 cases in each group.The control group was treated with milrinone,while the observation group was treated with milrinone combined with rhBNP,both groups received continuous treatment for 7 days.Compare the clinical efficacy,cardiac function,myocardial markers,and occurrence of adverse reactions between two groups.Results The total effective rate of the observation group was 95.56%,which was higher than 75.56%of the control group,the difference was statistically significant(P<0.05).After treatment,the left ventricular ejection fraction in both groups were higher than those before treatment,and the observation group was higher than that in the control group,the left ventricular end diastolic diameter and left ventricular end systolic diameter in both groups were shorter than those before treatment,and the observation group were shorter than those in the control group,the differences were statistically significant(P<0.05);the levels of N-terminal pro brain natriuretic peptide in both groups were lower than those before treatment,and the observation group was lower than that in the control group,the difference was statistically significant(P<0.05).Comparison of the incidence of adverse reactions between two groups,the difference was not statistically significant(P>0.05).Conclusion The rhBNP combined with milrinone has a significant therapeutic effect on patients with CHF,which can effectively promote the improvement of cardiac function,reduce myocardial marker levels,and has high safety.

关 键 词：充血性心力衰竭 重组人脑利钠肽 米力农 心功能 心肌标志物 

分 类 号：R541.6[医药卫生—心血管疾病]